Gut Bacteria Overgrowth May Explain Symptoms After Cancer Surgery, Review Finds

For millions of cancer survivors, the end of surgery is not the end of digestive trouble. Abdominal pain, bloating, diarrhea, nausea, and unexplained weight loss frequently persist for years after curative operations for esophageal, gastric, colorectal, pancreatic, and biliary cancers, and in many patients the cause has never been clear. A new narrative review published in Annals of Gastroenterological Surgery argues that one overlooked suspect deserves far more attention: small intestinal bacterial overgrowth, or SIBO, a condition in which bacteria that normally reside in the colon proliferate in the small intestine, where they ferment nutrients and disrupt absorption. The review synthesizes evidence from studies published through July 2026 and delivers a sobering message: positive tests for SIBO are common after gastrointestinal cancer surgery, but the science behind what those tests actually mean in surgically altered bodies is far shakier than the numbers suggest.

The scale of the problem is considerable. According to GLOBOCAN 2022 estimates cited in the review, roughly 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide in a single year, and curative surgery remains the cornerstone of treatment for gastrointestinal malignancies. Yet the same operations that remove tumors also dismantle the anatomical and physiological defenses that keep bacteria out of the small bowel. The review, based on a systematic PubMed/MEDLINE search through July 1, 2026, identifies four principal mechanisms by which surgery promotes overgrowth: impaired motility, loss of gastric acid, structural changes to the gut, and disruption of the microbiome. Each mechanism maps directly onto specific operations, and understanding that mapping is central to interpreting the clinical studies that follow.

Motility is perhaps the most fundamental defense. Coordinated peristalsis sweeps bacteria downstream before they can colonize, but surgical manipulation, vagal nerve injury, and reconstruction can slow or redirect that flow, creating stasis in which bacteria multiply freely. In esophageal cancer surgery, the stomach is typically reshaped into a conduit that replaces the esophagus, altering gastric emptying and vagal signaling. In gastric cancer surgery, reconstructions such as Billroth II and Roux-en-Y can create blind loops where contents pool and ferment. In colorectal surgery, removal of the ileocecal valve during right-sided hemicolectomy eliminates the mechanical barrier that normally prevents colonic bacteria from migrating backward into the small intestine. Meanwhile, gastrectomy removes the acid barrier that kills ingested microbes, and proton pump inhibitors, commonly prescribed after these operations, may compound the effect by further suppressing acid secretion.

The microbiome adds another layer of complexity. Gastrectomy and esophagectomy have been shown to shift microbial composition, increasing facultative anaerobes and reducing diversity, which weakens colonization resistance against pathogens. Perioperative antibiotics, altered nutrient flow, and changes in bile acid metabolism all contribute to this dysbiosis. Once overgrowth takes hold, it can perpetuate itself: abnormal fermentation and nutrient malabsorption damage the mucosa and fuel inflammation, creating a vicious cycle. Surgical stress, malnutrition, and cancer-related immune dysfunction can further weaken the intestinal barrier, and severe overgrowth may theoretically worsen nutritional status by consuming vitamin B12 and deconjugating bile acids, impairing fat absorption and fat-soluble vitamin uptake. Whether this actually drives postoperative weight loss and sarcopenia, however, remains biologically plausible rather than clinically proven.

Diagnosing SIBO in this population is where the story turns technically thorny. The traditional gold standard, quantitative culture of duodenal or jejunal aspirate at a threshold of 10,000 colony-forming units per milliliter, is invasive, prone to contamination, and impractical to repeat. Most clinicians therefore rely on breath testing: the patient drinks glucose, and if bacteria in the small intestine ferment it, hydrogen and methane rise in exhaled breath. Under current consensus criteria, a hydrogen rise of at least 20 parts per million above baseline within 90 minutes supports SIBO, while methane of at least 10 parts per million at any point is now classified separately as intestinal methanogen overgrowth, since methane is produced by archaea rather than bacteria. Meta-analytic data show the glucose breath test achieves roughly 54 to 63 percent sensitivity and 83 to 86 percent specificity, figures that are modest even before surgery enters the picture.

That caveat matters enormously, because surgery rewires transit. If the glucose bolus races through a reconstructed gut and reaches the colon within the test window, colonic fermentation gets misread as small-intestinal overgrowth. The most striking demonstration came from Lin and Massey, who paired glucose breath testing with scintigraphy in 139 patients. Of 46 positive breath tests, 22, or 48 percent, were false positives, with the gas rise occurring only after the substrate reached the cecum. Among patients with prior upper gastrointestinal surgery, colonic fermentation explained 65 percent of false positives, compared with 13 percent in those without surgery. The American College of Gastroenterology only conditionally recommends breath testing in symptomatic patients with previous luminal surgery, based on very low evidence, and the review’s authors stress that thresholds validated in anatomically normal patients may simply not apply after cancer resection.

The postoperative studies themselves reveal how messy the picture is. After esophagogastric cancer surgery, breath-test positivity ranged from 52.9 percent in a symptomatic cohort to 73.3 percent in a protocol-based study of 45 patients, while a prospective study of 45 disease-free survivors found evidence of SIBO in 38 percent alongside malabsorption in 73 percent. After gastrectomy, positivity swung from 29.7 percent to 77.6 percent depending on the diagnostic criteria used, and one study that added a 45-minute analysis to guard against transit-related false positives found no clear link between positive tests and nutritional status. In colorectal cancer, one study found 41.9 percent positivity versus 6.7 percent in healthy controls, with symptoms improving after rifaximin, but a case-control study after right-sided hemicolectomy found nearly identical positivity in patients with chronic loose stools and asymptomatic controls, 73 versus 74 percent, while bile acid malabsorption was far more common in the symptomatic group at 82 versus 37 percent.

That last finding may be the review’s most clinically important lesson: a positive breath test does not automatically explain a patient’s symptoms. Bile acid malabsorption, exocrine pancreatic insufficiency, dumping syndrome, carbohydrate intolerance, medication effects, strictures, infections, and cancer recurrence can all mimic or coexist with SIBO. The authors propose a pragmatic framework: evaluate persistent diarrhea, bloating, steatorrhea, or weight loss in the context of the specific reconstruction, exclude alternative and coexisting diagnoses first, and only then consider breath testing, interpreting results cautiously against the surgical anatomy. They also flag confounders that most studies ignored, including proton pump inhibitor duration, chemotherapy and radiotherapy effects on the gut, opioids that slow motility, and antibiotics that distort breath gas production. Evidence after pancreatic and biliary cancer surgery is thinner still; in one retrospective cohort of 545 pancreatic resection patients, breath testing was performed in only eight selected patients, seven of whom tested positive, a figure that cannot be generalized.

Treatment evidence is similarly indirect. In the only direct postoperative trials, rifaximin at 1200 milligrams daily for ten days improved symptoms, especially diarrhea, in colorectal cancer patients but normalized breath tests in only a third, while postgastrectomy patients showed an overall antibiotic failure rate of 67.6 percent, with positivity persisting in nearly 95 percent after rifaximin and 86 percent after subsequent metronidazole. By contrast, meta-analyses in general SIBO populations report breath-test normalization of about 51 percent with antibiotics versus 10 percent with placebo, rifaximin eradication rates near 71 percent, and probiotic combinations improving decontamination, while an exclusive elemental diet normalized lactulose breath tests in 80 percent of patients at 14 days. Recurrence looms over all of it: after successful rifaximin therapy, overgrowth returned in 12.6 percent of patients at three months and 43.7 percent at nine months, with older age, appendectomy history, and chronic proton pump inhibitor use as risk factors. None of these maintenance or prevention strategies has been tested in postoperative cancer patients.

The review’s authors close with a research agenda that reads like a call to modernize a neglected field: validate postoperative-specific breath-test criteria, incorporate objective transit measurement, apply microbiome sequencing and bile acid and metabolite profiling to identify high-risk patients, optimize rifaximin dosing and retreatment, and test whether treating overgrowth improves nutrition, body composition, quality of life, and survival. Until then, the message for clinicians is one of calibrated skepticism. SIBO belongs on the differential diagnosis for symptomatic cancer survivors, but the striking positivity rates reported after esophageal, gastric, and colorectal surgery reflect selection bias, heterogeneous protocols, and surgically accelerated transit as much as true disease. As survivorship care grows more sophisticated, distinguishing bacterial overgrowth from the many other legacies of cancer surgery may finally give these patients answers, and treatments, that actually work.

Subject of Research: Small intestinal bacterial overgrowth after gastrointestinal cancer surgery

Article Title: Small Intestinal Bacterial Overgrowth Following Gastrointestinal Cancer Surgery: Current Evidence and Future Perspectives

Article References: Aoyama, T., Cho, H., & Yoshikawa, T. (2026). Small Intestinal Bacterial Overgrowth Following Gastrointestinal Cancer Surgery: Current Evidence and Future Perspectives. Annals of Gastroenterological Surgery, Article ags3.70291. https://doi.org/10.1002/ags3.70291

Image Credits: AI Generated

DOI: 10.1002/ags3.70291

Keywords: SIBO, gastrointestinal cancer, breath testing, gastrectomy, esophagectomy, colorectal surgery, gut microbiome, bile acid malabsorption, rifaximin, postoperative symptoms, survivorship, probiotics